A recent study combined analysis of a patient's tumor genome and transcriptome sequences to guide treatment of tongue adenocarcinoma with Pfizer's Sutent (sunitinib) and Bayer's Nexavar (sorafenib).
In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.
